How to Help Your Patients Save Money on Breztri: A Provider's Guide to Savings Programs

Breztri Aerosphere is one of the most clinically effective inhaler options for COPD maintenance therapy — and now, following its April 2026 FDA approval for asthma, its patient population is expanding. But at $670–$930 per inhaler without insurance, cost is among the top reasons patients don't start or stay on Breztri. As a prescriber, equipping your team with a clear understanding of available savings programs can directly improve patient adherence and outcomes.

Understanding the Cost Landscape for Breztri in 2026

Breztri Aerosphere has no generic equivalent (none expected until approximately 2038). This means the full burden of brand-name pricing falls on patients without commercial insurance or with inadequate formulary coverage. Here's the pricing landscape your patients face:

Retail (no insurance): $670–$930 per 30-day inhaler

With GoodRx: As low as $655–$674 per inhaler

With SingleCare: As low as ~$572 per inhaler at participating pharmacies

Commercial insurance (Tier 3–4, after prior auth): Typically $50–$200 copay per fill, depending on plan design

With AstraZeneca Zero Pay: As little as $0 for eligible commercially insured patients

Program 1: AstraZeneca Breztri Zero Pay (Commercial Insurance)

The Breztri Zero Pay copay card is the highest-impact savings program for commercially insured patients and should be the first resource your team mentions when prescribing Breztri to any patient with employer or private insurance.

Key features:

AstraZeneca covers up to 100% of out-of-pocket copay costs for eligible patients

No income requirements for commercial insurance patients

Patients can apply online (breztri.com), by text, or by phone

NOT eligible for: Medicare, Medicaid, TRICARE, or other federal/state government insurance programs

Recommended workflow: At the point of prescribing, have your MA direct commercially insured patients to breztri.com or provide the Zero Pay program phone number. This takes 5–10 minutes and can eliminate cost as a barrier before the patient ever reaches the pharmacy.

Program 2: AZ&Me Patient Assistance Program (Medicare and Uninsured)

For your patients on Medicare Part D or without any insurance who meet income criteria, AZ&Me provides Breztri at no charge. This is a critical safety net for elderly COPD patients on fixed incomes — the demographic most likely to be prescribed triple therapy and most likely to face catastrophic cost barriers.

Program details:

Phone: 1-800-292-6363

Your office can complete enrollment paperwork on behalf of the patient

Income-based eligibility — determined on a case-by-case basis

A Bridge Program is available for patients experiencing temporary coverage gaps

Consider having a designated patient assistance coordinator in your practice who can identify and enroll eligible patients during post-visit follow-up calls.

Program 3: Pharmacy Discount Cards (GoodRx, SingleCare, Inside Rx)

For patients who don't qualify for the manufacturer programs or need immediate relief, pharmacy discount cards can reduce the cash price of Breztri. GoodRx currently shows prices as low as $655–$674 per inhaler; SingleCare as low as approximately $572 at participating pharmacies.

Prescriber guidance for discount cards:

Discount cards cannot be used simultaneously with insurance — the patient chooses one or the other at the pharmacy

Cannot be used with Medicare or Medicaid

Best use: patients with high-deductible commercial plans where discount card price may beat their deductible-era copay

Program 4: Mail-Order 90-Day Supply (Insurance)

Many commercial insurance and Medicare Advantage plans offer lower per-unit costs for 90-day mail-order fills versus 30-day retail fills. For stable patients who will be on Breztri long-term, mail-order is both more cost-effective and reduces the risk of access interruptions from pharmacy stock issues. Encourage patients to ask their insurance about mail-order specialty pharmacy options when you're prescribing Breztri for ongoing maintenance therapy.

When Cost Is Prohibitive: Clinical Alternatives to Consider

When all savings programs have been exhausted and Breztri remains unaffordable, consider these evidence-based alternatives:

Trelegy Ellipta: The only other FDA-approved fixed-dose triple-combination inhaler. Similar list price to Breztri, but may have different insurance tier coverage. GSK also has a copay savings program (Trelegy Savings Card). Once-daily dosing may improve adherence.

Generic budesonide/formoterol (generic Symbicort) + tiotropium (generic Spiriva): Replicates triple therapy at dramatically lower cost. Generic Symbicort: approximately $50–$150/month. Generic tiotropium is becoming available. Total two-inhaler cost may be $100–$250/month — a fraction of branded triple therapy.

ICS/LABA + LAMA from same family: Breo Ellipta (ICS/LABA) + Incruse Ellipta (LAMA) provides triple therapy with once-daily dosing in a familiar device format. May have better insurance coverage than Breztri in some plans.

Building a Savings Referral Workflow in Your Practice

A structured approach maximizes the number of patients who successfully access cost savings:

At time of prescribing: Identify insurance type (commercial vs. Medicare vs. uninsured). Route to appropriate program.

Submit prior authorization proactively: Don't wait for a pharmacy rejection to trigger the PA process.

Follow up at 2 weeks: Call or message to confirm the patient received their Breztri and didn't abandon the prescription due to cost or access barriers.

Annual review: Insurance formularies change yearly. Re-evaluate coverage status and savings program eligibility at each annual renewal period.

For patients struggling to locate Breztri at pharmacies near them — a separate but related access barrier — recommend medfinder for providers, which calls pharmacies on behalf of patients and texts them which ones have Breztri in stock. This eliminates the combined frustration of cost uncertainty AND stock uncertainty.

For the full clinical context on Breztri supply status and prescribing considerations, see our Breztri shortage update for providers.